Literature DB >> 20462722

Development of a selective competitive receptor binding assay for the determination of the affinity to NR2B containing NMDA receptors.

Dirk Schepmann1, Bastian Frehland, Kirstin Lehmkuhl, Bastian Tewes, Bernhard Wünsch.   

Abstract

A selective, rapid and efficient competitive binding assay for the determination of the affinity of compounds towards the ifenprodil binding site of NR2B subunit containing NMDA receptors has been developed. In the assay system, [(3)H]ifenprodil was used as radioligand and membrane homogenates from L(tk-) cells stably expressing recombinant human NR1a/NR2B receptors served as the receptor material. Sonication of the cells during work-up, performing all steps with 96-well multiplates and using a solid scintillator represent particular features of this assay. The binding kinetics was investigated by saturation and association/dissociation experiments. [(3)H]ifenprodil bound to a single, saturable site on human recombinant NR1a/NR2B receptors, resulting in a B(max)-value of 25.8 pmol/microg protein and K(d)-value of 7.6+/-2.3 nM (SEM). The dissociation rate constant (k(off)) was 0.03861 min(-1) and the association rate constant k(on) resulted in 0.00625 nM(-1)min(-1). The specificity of the assay was proved with cells not treated with dexamethasone, which has to be added to induce NMDA receptor synthesis of the cells. Additionally, the absence of alpha(1), sigma(1) and sigma(2) receptors was shown. The K(i)-values of the NR2B ligands ifenprodil and eliprodil determined with the new assay are in good accordance with reported data. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20462722     DOI: 10.1016/j.jpba.2010.04.014

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  7 in total

1.  Novel GluN2B selective NMDA receptor antagonists: relative configuration of 7-meth-oxy-2-methyl-2,3,4,5-tetra-hydro-1H-3-benzazepin-1-ols.

Authors:  Bastian Tewes; Bastian Frehland; Roland Fröhlich; Bernhard Wünsch
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2016-04-15

2.  Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?

Authors:  Yoshihiro Shuto; Simone Thum; Louisa Temme; Dirk Schepmann; Masato Kitamura; Bernhard Wünsch
Journal:  Medchemcomm       Date:  2017-03-17       Impact factor: 3.597

3.  Synthesis and receptor binding of thiophene bioisosteres of potent GluN2B ligands with a benzo[7]annulene-scaffold.

Authors:  Sören Baumeister; Dirk Schepmann; Bernhard Wünsch
Journal:  Medchemcomm       Date:  2019-01-10       Impact factor: 3.597

4.  Crystal structure of (1S*,2R*)-7-benz-yloxy-2-methyl-3-tosyl-2,3,4,5-tetra-hydro-1H-3-benz-azepin-1-ol: elucidation of the relative configuration of potent allosteric GluN2B selective NMDA receptor antagonists.

Authors:  Bastian Tewes; Bastian Frehland; Roland Fröhlich; Bernhard Wünsch
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2016-04-15

5.  A common mechanism allows selective targeting of GluN2B subunit-containing N-methyl-D-aspartate receptors.

Authors:  Bernhard Wünsch; Guiscard Seebohm; Julian A Schreiber; Dirk Schepmann; Bastian Frehland; Simone Thum; Maia Datunashvili; Thomas Budde; Michael Hollmann; Nathalie Strutz-Seebohm
Journal:  Commun Biol       Date:  2019-11-15

6.  Characterization in nonhuman primates of (R)-[18F]OF-Me-NB1 and (S)-[18F]OF-Me-NB1 for imaging the GluN2B subunits of the NMDA receptor.

Authors:  MingQiang Zheng; Hazem Ahmed; Kelly Smart; Yuping Xu; Daniel Holden; Michael Kapinos; Zachary Felchner; Ahmed Haider; Gilles Tamagnan; Richard E Carson; Yiyun Huang; Simon M Ametamey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-02-02       Impact factor: 10.057

7.  [2.2]Paracyclophane-Based TCN-201 Analogs as GluN2A-Selective NMDA Receptor Antagonists.

Authors:  Remya Rajan; Dirk Schepmann; Ruben Steigerwald; Julian A Schreiber; Ehab El-Awaad; Joachim Jose; Guiscard Seebohm; Bernhard Wünsch
Journal:  ChemMedChem       Date:  2021-08-03       Impact factor: 3.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.